Unique ID issued by UMIN | UMIN000006585 |
---|---|
Receipt number | R000007779 |
Scientific Title | Regenerative treatment for tympanic membrane perforation |
Date of disclosure of the study information | 2011/10/21 |
Last modified on | 2011/10/21 14:09:50 |
Regenerative treatment for tympanic membrane perforation
Regenerative treatment for tympanic membrane perforation
Regenerative treatment for tympanic membrane perforation
Regenerative treatment for tympanic membrane perforation
Japan |
Perforation of tympanic membrane
Oto-rhino-laryngology |
Others
NO
To assess the efficacy and safety of this tissue engineering therapy for the treatment of tympanic membrane perforation (TMP)
Safety,Efficacy
Exploratory
Explanatory
Phase II
Closure of tympanic membrane perforation 3 months after the treatment
1)Efficacy
Improvement of hearing level 3 months after the treatment
2)Safety
Adverse events
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine | Maneuver |
Tissue engineering therapy for the treatment of tympanic membrane perforation
20 | years-old | <= |
Not applicable |
Male and Female
1. Chronic otitis media with TMP OR
Old traumatic TMP, OR Residual TMP following surgical treatments, OR TMP after the insertion of a ventilation tube in patients with otitis media with effusion
2. On microscope, perfect dry TMP and no active inflammation in the inner, middle, or outer ear; no invasion of epitherium into middle ear vaity and no cholesteatoma
3. Based on temporal bone CT,
a. Well pneumatized mastoid (MC2 or MC3) defined by the Japan Otological Society
b. Absence of abnormal soft tissue mass
c. Normal ossicles
4. Hearing improvement upon patch test
5. Signed written informed consent to participate in the trial
1. TMP due to burn
2. Postoperatively re-perforated TM or patients who underwent surgeries in the inner, middle, or outer ear
3. Poor development of the mastoid pneumatization(MC0 or MC1) defined by the Japan Otological Society
4. Unable to see the whole edge of TMP due to narrow external auditory canal
5. Active infection or inflammation in the inner or middle ear
6. Uncontrolled diabetes mellitus or autoimmune diseases
7. Patients treated with immunosuppressive or anticancer drugs
8. Allergy to drugs (lidocaine, Trafermin/Fibrast, fibrin glue(Bolheal, Beriplast)) or gelatin sponge(Spongel)
9. Requirement for antiplatelet or anticoagulant drugs
10. Females who are pregnant or desire childbearing
11. Patients judged as being inappropriate for this trial by investigators
10
1st name | |
Middle name | |
Last name | Shin-ichi Kanemaru, M.D., Ph.D. |
Medical Research Institute, Kitano Hospital
Department of Otolaryngology–Head and Neck Surgery
2-4-20 Ohgimachi, Kitaku, Osaka, 530-8480, Japan
+81-6-6312-8824
1st name | |
Middle name | |
Last name | Shin-ichi Kanemaru, M.D., Ph.D. |
Medical Research Institute, Kitano Hospital
Department of Otolaryngology–Head and Neck Surgery
2-4-20 Ohgimachi, Kitaku, Osaka, 530-8480, Japan
+81-6-6312-8824
kanemaru@ent.kuhp.kyoto-u.ac.jp
The Foundation for Biomedical Research and Innovation
The Foundation for Biomedical Research and Innovation
Non profit foundation
Japan
Medical Research Institute, Kitano Hospital
Kobe City Medical Center General Hospital
NO
2011 | Year | 10 | Month | 21 | Day |
Unpublished
Open public recruiting
2011 | Year | 09 | Month | 22 | Day |
2011 | Year | 10 | Month | 01 | Day |
2011 | Year | 10 | Month | 21 | Day |
2011 | Year | 10 | Month | 21 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000007779